Currency In USD
| Previous Close | 46.99 |
| Open | 46.99 |
| Day High | 46.99 |
| Day Low | 46.99 |
| 52-Week High | 62 |
| 52-Week Low | 28.21 |
| Volume | 5.01M |
| Average Volume | 5.85M |
| Market Cap | 3.54B |
| PE | -13.78 |
| EPS | -3.41 |
| Moving Average 50 Days | 45.88 |
| Moving Average 200 Days | 41.19 |
| Change | 0.01 |
Data not available
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
GlobeNewswire Inc.
Oct 21, 2025 6:00 AM GMT
Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profileSTAMFORD, Conn., Oct. 21, 2
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
GlobeNewswire Inc.
Aug 18, 2025 1:10 PM GMT
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumorsSTAMFORD, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt,
European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire Inc.
Jul 18, 2025 3:30 PM GMT
– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringW